Changes in Hong Kong stocks | Peger Biopharmaceutical-B (02565) rose more than 6%, the first batch of commercialized prescriptions in the country landed and received a second equity of about HK$49 million

The Zhitong Finance App learned that Peger Biopharmaceutical-B (02565) rose more than 6%. As of press release, it had risen 6.1% to HK$7.48, with a turnover of HK$30.156,700.

According to the news, on July 22, Peger Biotech announced that Pidacang® has successively issued the first batch of commercial prescriptions at many medical institutions across the country, including Peking University People's Hospital and the Second Xiangya Hospital of Central South University, and implemented the first batch of prescriptions through online medical service channels, and officially entered the clinical application and patient use stage.

Following the issuance of the first batch of commercial prescriptions in the country, the second equity payment terms agreed in the commercialization cooperation agreement between the company and Tengrui Pharmaceuticals were simultaneously reached, amounting to about HK$49 million. In addition to the initial equity amount of approximately HK$61 million previously received, Peger Biotech has now collected and triggered a total of approximately HK$110 million in equity.